Skip to main content
FastDOL

Establishment profile

MAYO CLINIC

200 1ST STREET SW, ROCHESTER, MN, 55905
Operated by Mayo Clinic · 1 of 32 establishments
621111 — Offices of Physicians (except Mental Health Specialists)
EIN 411404075

Download as PDF →

OSHA inspections
4
over 35 years
Violations
35
$1,530 in penalties
Penalties
$1,530
$44 avg
Violations across 3 federal agencies
Enforcement actions from multiple agencies may indicate systemic compliance issues across functions.
Accident investigations on record
1 OSHA follow-up

Summary

MAYO CLINIC has accumulated 35 OSHA violations across 4 inspections over 35 years of recorded history, with $1,530 in total assessed penalties.

The establishment sits in the 100th percentile for violations within its industry-state peer group of 33 employers. Inspection frequency runs at the 100th percentile. The most recent enforcement activity was recorded 9 years ago.

Federal records were found in 3 of 15 sources. Sources without matching records returned empty for this establishment.

Agency coverage

MAYO CLINIC appears in OSHA workplace safety, WHD wage enforcement, NLRB labor relations, and OFLC visa and labor certification (historical) records only. No matching records were found in MSHA mine safety, EPA environmental compliance, FMCSA motor carrier registration, SAM.gov federal debarment, CMS nursing home enforcement, UVA Corporate Prosecution Registry, CPSC product recalls, or NHTSA vehicle recalls.

OSHA workplace safety

Inspections
4
0.1 / yr · last 35 yrs
Violations
35
1.0 / yr
Penalties
$1,530
$44 avg / violation
11% serious89% other
Inspection trigger · complaint
2 of 4
Inspection trigger · planned
1 of 4

50% of inspections at this establishment produced violations, with 2 inspections producing serious-or-greater violations.

Most-cited OSHA standards

Top OSHA standards cited at this employer, ranked by citation count. Standards (CFR sections) cluster citations into safety themes -- machine guarding, lockout-tagout, hazard communication, fall protection, process safety, etc. A concentration on one or two sections reveals a pattern that individual citations don’t. 20 distinct standards shown · 23 citations in this view · $1,530 in penalties.

CFR sectionCitationsInspectionsTotal penaltyFirst citedLast cited
29 CFR 1910.0219 D0122$630Jul 1991Dec 2013
29 CFR 1910.0212 A0121$264Jul 1991Jul 1991
29 CFR 5206.07000121$180Jul 1991Jul 1991
29 CFR 5205.10200111$264Jul 1991Jul 1991
29 CFR 1910.0178 K0111$192Jul 1991Jul 1991
29 CFR 1910.0106 D04 IV11—Jul 1991Jul 1991
29 CFR 1910.0106 E02 IVD11—Jul 1991Jul 1991
29 CFR 1910.0106 E06 II11—Jul 1991Jul 1991
29 CFR 1910.0110 B06 VI11—Jul 1991Jul 1991
29 CFR 1910.0110 B09 VIIC11—Jul 1991Jul 1991
29 CFR 1910.0133 A0111—Jul 1991Jul 1991
29 CFR 1910.0141 G0411—Jul 1991Jul 1991
29 CFR 1910.0151 C11—Jul 1991Jul 1991
29 CFR 1910.0158 C0411—Jul 1991Jul 1991
29 CFR 1910.0184 E02 II11—Jul 1991Jul 1991
29 CFR 1910.0213 B0311—Jul 1991Jul 1991
29 CFR 1910.0254 D09 III11—Jul 1991Jul 1991
29 CFR 1910.0303 B01 III11—Jul 1991Jul 1991
29 CFR 1910.0303 G02 I11—Jul 1991Jul 1991
29 CFR 1910.0304 A0211—Jul 1991Jul 1991

Source: OSHA inspection citations (violation_detail). CFR section codes can be looked up at osha.gov/laws-regs for the formal standard text. Per-inspection detail and the specific violation descriptions are available by expanding individual inspections below.

Peer comparison

100th

Worse on violations than nearly every other employer in NAICS 6211 within MN. Peer group: 33 employers. This establishment has 35 OSHA violations; peer median is 0.

Fewer violationsMore violations
Penalty percentile
97th
peer median: $0
Inspection frequency
100th
peer median: 1

Safety self-report (OSHA 300A)

Recordable injury rates the employer filed with OSHA’s Injury Tracking Application. DART covers cases with days away, restricted, or transferred; TRIR is the total recordable case rate.

DART rate
0.0
vs industry
−0.4
TRIR
0.0
vs industry
−1.8

Reported for 64 average annual employees at this establishment.

Source: OSHA ITA Form 300A (employer self-reported). Rates are per 100 full-time equivalent workers. Establishments below the ~10-FTE threshold are not required to report.

Industry benchmark

Industry avg TRIR
1.8
BLS SOII 2024
Industry avg DART
0.4
BLS SOII 2024
Self-reported TRIR
0.0
OSHA ITA Form 300A (employer self-reported)

BLS rates reflect industry-wide averages. Self-reported figures come from OSHA’s Injury Tracking Application; absence of self-reported data does not necessarily indicate non-compliance — many establishments fall below the ITA reporting threshold.

Inspection breakdown

Planned
1
Complaint
2
Follow-up
1

Complaint- and accident-triggered inspections are stronger risk signals than routine planned inspections.

OSHA severe injury reports

No severe injury reports (hospitalization, amputation, or loss of an eye) on file under 29 CFR 1904.39 for MAYO CLINIC. Verify directly with Occupational Safety and Health Administration →

Activity timeline

Data refreshed
Weekly
First OSHA inspection
—
Most recent activity
9 years ago

No federal enforcement activity has been recorded against this establishment in 9+ years. Most recent activity: 9 years ago. Data on this page is refreshed weekly.

Wage & Hour Division (WHD)

Cases
2
Back wages owed
$0
Employees affected
2

Department of Labor Wage & Hour Division — minimum-wage, overtime, child-labor, FMLA, and prevailing-wage enforcement.

Wage and hour cases

Closed DOL Wage & Hour Division cases (FLSA, FMLA, H-2B, MSPA, and related statutes). Backwages reflect amounts the agency assessed; civil penalty (CMP) is a separate fine levied on top, where the statute provides for one (FLSA / H-1B / H-2A / MSPA / FMLA / EPPA / FLSA Child Labor; other acts have no CMP column in DOL’s data). The Statutes column lists which laws each case cited. 2 cases · $0 in backwages · 2 workers affected

Case periodIndustryStatutesViolationsWorkersBackwagesCivil penalty
Jul 2015 – Jul 2017Offices of Physicians——1——
Jun 2014General Medical and Surgical Hospitals——1——

Source: DOL WHD enforcement database. Cases shown reflect those the agency has closed and made public. A violation count is the agency’s tally of cited violations (one violation can affect many workers); the workers column counts distinct employees the agency found to be affected.

Mine safety (MSHA)

No MSHA mine safety violations on file for MAYO CLINIC. Verify directly with Mine Safety and Health Administration →

Labor relations (NLRB)

Company-level in MN — for Mayo Clinic, not this location alone

Total cases
6
Unfair labor practice
5
Representation (union)
1

National Labor Relations Board — unfair labor practice charges and union representation cases. The NLRB records cases at the company/regional level (no worksite address), so these are matched by company name and state and may span other Mayo Clinic locations in the same state.

NLRB cases

National Labor Relations Board cases involving this employer. Includes unfair labor practice (ULP) filings and representation election proceedings. NLRB enforcement is process-driven; no per-case monetary penalty is assessed (remedies are case-by-case backpay orders, posting requirements, election re-runs, etc.). 6 cases · 5 ULP · 1 representation

Case numberTypeFiledClosedStatusRegion
18-CA-344262Unfair labor practiceJun 2024Sep 2024ClosedRegion 18, Minneapolis, Minnesota
18-CA-331480Unfair labor practiceDec 2023May 2024ClosedRegion 18, Minneapolis, Minnesota
18-CA-308143Unfair labor practiceDec 2022Apr 2024ClosedRegion 18, Minneapolis, Minnesota
18-CA-285105Unfair labor practiceOct 2021Dec 2021ClosedRegion 18, Minneapolis, Minnesota
18-CA-181534Unfair labor practiceAug 2016Jan 2017ClosedRegion 18, Minneapolis, Minnesota
18-RC-149346Representation electionApr 2015May 2015ClosedRegion 18, Minneapolis, Minnesota

Source: NLRB case files. Rows shown are those the agency has published. Region numbers (1–31) correspond to NLRB's geographic offices.

Visa & labor certification (OFLC) — historical

Total applications
815
Certified
809
Avg wage ratio
1.56x
H-1BE-3 Australian

Office of Foreign Labor Certification — labor condition applications for H-1B, H-2A, H-2B visa programs. Wage ratio = offered / prevailing wage. Historical data only: DOL ended OFLC Performance Data Disclosure publication in 2026, so the figures above reflect filings through the last ingested cycle and are not being refreshed. Treat as a historical snapshot, not a current signal.

Environmental compliance (EPA)

No EPA inspections or formal enforcement actions on file for MAYO CLINIC. Verify directly with Environmental Protection Agency →

Federal criminal prosecution record

No federal criminal prosecutions, plea agreements, or deferred-prosecution agreements on file for MAYO CLINIC. Verify directly with UVA Corporate Prosecution Registry →

Federal contracts

This location

Obligated (5-yr)
$104.7M
Obligated (all-time)
$434.6M
Awards
1,160
Top agency
Department of Justice
$237.1M
Company-wide — MAYO FOUNDATION (across 19 entities)
Obligated (5-yr)
$49.4M
Obligated (all-time)
$420.9M
Awards (all-time)
1,740

Consolidated across all USAspending recipient entities under this corporate parent — not attributable to this single location.

Top agencies by obligation (this location)
Department of Justice$237.1M
Department of Health and Human Services$127.8M
Department of Defense$62.8M
Department of Veterans Affairs$6.1M
National Aeronautics and Space Administration$416K
Largest awards (top 50 of 1,160)
  • Department of Health and Human Services
    PRECISION MEDICINE INITIATIVE COHORT PROGRAM BIOBANK
    assistance · Last action 2026-01-06
    $180,342,068
  • Department of Health and Human Services
    MAYO COMPREHENSIVE CANCER CENTER GRANT
    assistance · Last action 2025-12-02
    $106,749,839
  • Department of Health and Human Services
    STATISTICS AND DATA CENTER FOR THE ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY
    assistance · Last action 2026-06-12
    $104,371,215
  • Department of Health and Human Services
    ARTFL LEFFTDS LONGITUDINAL FRONTOTEMPORAL LOBAR DEGENERATION (ALLFTD)
    assistance · Last action 2026-06-18
    $82,572,681
  • Department of Health and Human Services
    MAYO CLINIC CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCE (CCATS)
    assistance · Last action 2025-08-13
    $70,838,088
  • Department of Health and Human Services
    SUPPORT EAP TO FACILITATE THE USE OF HUMAN CONVALESCENT PLASMA TO TREAT HOSPITALIZED CORONAVIRUS-2 (SARS-COV-2) COVID-19 PATIENTS
    contract · Last action 2020-08-14
    $48,927,887
  • Department of Health and Human Services
    ALZHEIMER DISEASE PATIENT REGISTRY
    assistance · Last action 2025-05-09
    $39,658,783
  • Department of Health and Human Services
    MAYO CLINIC BREAST CANCER SPORE
    assistance · Last action 2025-09-02
    $38,450,771
  • Department of Health and Human Services
    MAYO CLINIC SPORE IN OVARIAN CANCER
    assistance · Last action 2025-08-27
    $32,533,692
  • Department of Health and Human Services
    TARGETING CELLULAR SENESCENCE TO EXTEND HEALTHSPAN
    assistance · Last action 2026-02-25
    $25,141,194
  • Department of Health and Human Services
    MAYO ALZHEIMER'S DISEASE RESEARCH CENTER
    assistance · Last action 2026-03-24
    $24,495,299
  • Department of Health and Human Services
    THE LYMPHOMA EPIDEMIOLOGY OF OUTCOMES (LEO) COHORT STUDY
    assistance · Last action 2025-06-10
    $22,101,202
  • Department of Health and Human Services
    MAYO CENTER FOR CELL SIGNALING IN GASTROENTEROLOGY
    assistance · Last action 2025-07-08
    $19,809,546
  • Department of Health and Human Services
    ALL OF US BIOBANK - IN 2017, THE ALL OF US (AOU) RESEARCH PROGRAM WAS ESTABLISHED TO REALIZE THE AMBITIOUS GOALS SET OUT BY THE PRECISION MEDICINE INITIATIVE PROPOSAL. THE GOAL OF THE AOU RESEARCH PROGRAM IS TO ENROLL ONE MILLION PEOPLE LIVING IN THE U.S. INTO A NATIONAL COHORT THAT BROADLY REPRESENTS THE U.S. POPULATION AND TO ACCELERATE PROGRESS TOWARD A NEW ERA OF PRECISION MEDICINE ON A LARGER SCALE THAN PREVIOUSLY POSSIBLE. OVER THE COURSE OF THE PAST 7 YEARS, THE AOU RESEARCH PROGRAM HAS ENROLLED 848,783 PARTICIPANTS WITH 608,145 PROVIDING BIOSPECIMENS, RESULTING IN 3,959,288 SAMPLES COLLECTED AND 14,521,323 ALIQUOTS CREATED AND STORED AT THE AOU BIOBANK HOUSED WITHIN THE MAYO CLINIC BIOREPOSITORIES PROGRAM. THE MAYO CLINIC BIOREPOSITORIES PROGRAM IS CAP ACCREDITED AND HAS BIOBANKING ACTIVITIES ESTABLISHED AT ALL THREE MAYO CLINIC SITES (ROCHESTER, MN, JACKSONVILLE, FL, AND PHOENIX, AZ). MAYO CLINIC HAS BEEN AN INTEGRAL MEMBER OF THE AOU TEAM SINCE ITS INCEPTION, SUPPORTING THE AOU RESEARCH PROGRAM THROUGH INPUT ON PROGRAM DEVELOPMENT AND EXECUTION OF ALL ACTIVITIES RELATED TO BIOSPECIMEN COLLECTION, PROCESSING, STORAGE, DISTRIBUTION, AND MANAGEMENT. THE OBJECTIVE OF THIS NEW PROPOSAL IS TO CONTINUE UTILIZING THE FULL RESOURCES AVAILABLE THROUGH THE MAYO CLINIC BIOREPOSITORIES PROGRAM TO EFFICIENTLY AND COST EFFECTIVELY SUPPORT THE AOU RESEARCH PROGRAM IN INNOVATIVE WAYS WITH RESPECT TO AOU BIOBANKING ACTIVITIES, NAMELY: BIOSPECIMEN COLLECTION, KIT ASSEMBLY, BIOSPECIMEN SHIPPING, RECEIPT, ACCESSIONING, TRACKING, PROCESSING, QUALITY ASSURANCE, STORAGE, AND DISTRIBUTION. MAYO CLINIC LABORATORIES IN ROCHESTER MN, THE THIRD LARGEST REFERENCE LABORATORY IN THE UNITED STATES, WILL CONTINUE TO SUPPORT AOU BIOBANK ACTIVITIES BY ENABLING EFFICIENT SPECIMEN TRANSPORTATION AND ROUTING BETWEEN AOU COLLECTION SITES AND THE AOU BIOBANK AT MAYO CLINIC. WHILE MAYO CLINIC ROCHESTER WILL CONTINUE TO SERVE AS THE PRIMARY SITE FOR AOU BIOBANK ACTIVITIES, THE BIOREPOSITORY GROUP AT MAYO CLINIC JACKSONVILLE WILL CONTINUE TO PROVIDE SUPPORT AS THE SECONDARY SITE FOR SAMPLE STORAGE, ENSURING THAT A SUBSET OF THE COHORT IS AVAILABLE AS A BACKUP. THE SPECIFIC AIMS OF THIS PROPOSAL ARE TO: 1) MAINTAIN EXISTING BIOSPECIMENS AND SUSTAIN BIOBANK OPERATIONS; 2) SUPPORT BIOBANK EXPANSION INITIATIVES, INCLUDING PEDIATRIC, REASSESSMENT, AND ANCILLARY STUDIES; AND 3) PROVIDE ONGOING COLLABORATION AND SUPPORT FOR THE AOU RESEARCH PROGRAM. OVERALL, THE COMBINED CAPABILITIES AND FACILITIES AVAILABLE THROUGH THE MAYO CLINIC BIOREPOSITORIES PROGRAM AND MAYO CLINIC LABORATORIES PROVIDE AN UNPARALLELED ABILITY TO COLLECT, ACCESSION, PROCESS, DISTRIBUTE, STORE, AND MANAGE VIRTUALLY ANY TYPE OF BIOSPECIMEN, WHILE MAINTAINING THE HIGHEST STANDARDS FOR BIOSPECIMEN QUALITY. AS DEMONSTRATED OVER THE COURSE OF THE PAST 7 YEARS, WE HAVE THE CAPACITY AND THE PROVEN CAPABILITIES TO SUPPORT ALL NEW INITIATIVES ON BEHALF OF THE AOU RESEARCH PROGRAM.
    assistance · Last action 2025-07-22
    $19,232,744
  • Department of Health and Human Services
    FFP PURCHASE ORDER FOR SITE REIMBURSEMENT, ORTHO TESTING, NAB TESTING, AND TREATMENT/CONTROL STUDY AT THE MAYO CLINIC CCP EAP
    contract · Last action 2020-10-14
    $17,509,398
  • Department of Health and Human Services
    LONGITUDINAL IMAGING BIOMARKERS OF DISEASE PROGRESSION IN DLB
    assistance · Last action 2025-08-20
    $16,901,125
  • Department of Health and Human Services
    MAYO CLINIC HEPATOBILIARY SPORE
    assistance · Last action 2026-03-23
    $15,914,851
  • Department of Health and Human Services
    EMR PHENOTYPE AND COMMUNITY ENGAGED GENOMIC ASSOCIATIONS
    assistance · Last action 2025-07-15
    $15,860,142
  • Department of Health and Human Services
    PAUL CALABRESI PROGRAM IN CLINICAL-TRANSLATIONAL RESEARCH AT MAYO CLINIC
    assistance · Last action 2026-02-17
    $15,407,472
  • Department of Health and Human Services
    INSTITUTIONAL CAREER DEVELOPMENT CORE
    assistance · Last action 2025-08-08
    $13,574,607
  • Department of Health and Human Services
    BETA1-SELECTIVE BLOCKADE FOR PREVENTION OF POSTMENOPAUSAL BONE LOSS: A RANDOMIZED CONTROLLED TRIAL - OSTEOPOROSIS IS A DISEASE OF AGING THAT LEADS TO ~2 MILLION FRACTURES AND ~$17 BILLION IN HEALTHCARE COSTS ANNUALLY. ALTHOUGH SEVERAL DRUGS ARE FDA-APPROVED FOR THE TREATMENT OF OSTEOPOROSIS, THE POTENTIAL FOR SERIOUS SIDE EFFECTS (E.G., OSTEONECROSIS OF THE JAW, ATYPICAL FEMUR FRACTURES) HAS LED MOST PHYSICIANS TO USE THESE DRUGS ONLY FOR THE TREATMENT, BUT NOT THE PREVENTION, OF OSTEOPOROSIS. THIS HAS LED TO THE CURRENT SITUATION WHERE MOST POSTMENOPAUSAL WOMEN MUST WAIT UNTIL THEY DEVELOP FRANK OSTEOPOROSIS (I.E., FRACTURES, OR SUFFICIENTLY HIGH FRACTURE RISK) TO BEGIN DRUG THERAPY. AS SUCH, THERE IS A COMPELLING NEED FOR NOVEL, RELATIVELY LOW-RISK AND LOW-COST PHARMACOLOGICAL APPROACHES TO PREVENT OSTEOPOROSIS. THE CURRENT PROPOSAL AIMS TO TRANSLATE EVIDENCE FROM RODENT STUDIES SHOWING THAT THE SYMPATHETIC NERVOUS SYSTEM (SNS) IS AN IMPORTANT REGULATOR OF BONE METABOLISM TO A SIMPLE, COST-EFFECTIVE, AND SAFE APPROACH FOR OSTEOPOROSIS PREVENTION. IN KEY PRELIMINARY DATA, WE OBTAINED MULTIPLE LINES OF EVIDENCE TO ESTABLISH CLEARLY THE ROLE OF THE SNS IN REGULATING HUMAN BONE METABOLISM. A CRITICAL COMPONENT OF THESE DATA WAS A “PROOF-OF- CONCEPT” INTERVENTIONAL STUDY DEMONSTRATING THAT SS1-SELECTIVE BLOCKERS (ATENOLOL, NEBIVOLOL), BUT NOT A NON- SELECTIVE SS-AR BLOCKER (PROPRANOLOL), HAVE FAVORABLE EFFECTS ON BONE TURNOVER AND BONE MINERAL DENSITY (BMD) IN POSTMENOPAUSAL WOMEN. BASED ON THESE DATA, WE WILL PERFORM A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED 2 YEAR CLINICAL TRIAL ADDRESSING THE FOLLOWING SPECIFIC AIMS: (1) TEST THE HYPOTHESIS THAT TREATMENT WITH A WIDELY USED, INEXPENSIVE, AND RELATIVELY SS1-SELECTIVE BLOCKER (ATENOLOL) WILL PREVENT BONE LOSS AT THE LUMBAR SPINE AND FEMUR NECK AS ASSESSED BY DUAL-ENERGY X-RAY ABSORPTIOMETRY IN 420 POSTMENOPAUSAL WOMEN WITHOUT PRE-EXISTING OSTEOPOROSIS (AIM 1A); AND EVALUATE THE TOLERABILITY AND SAFETY OF ATENOLOL WHEN USED FOR THE PREVENTION OF BONE LOSS (AIM 1B). (2) EVALUATE THE EFFECTS OF ATENOLOL ON TRABECULAR AND CORTICAL BONE MICROARCHITECTURE USING HIGH RESOLUTION-PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY (AIM 2A), ON BONE TURNOVER MARKERS (AIM 2B), AND TEST WHETHER BASELINE MEASURES OF BONE TURNOVER OR OF SYMPATHETIC ACTIVITY (RESTING HEART RATE, PLASMA CATECHOLAMINE LEVELS) ARE PREDICTIVE OF THE BMD RESPONSE TO ATENOLOL OVER 2 YEARS (AIM 2C). (3) IN A SUBSET OF PATIENTS, EXPLORE THE UNDERLYING MOLECULAR AND CELLULAR MECHANISMS FOR THE EFFECTS OF SS1-SELECTIVE BLOCKADE ON BONE IN HUMANS USING ANALYSES OF OSTEOBLAST POPULATIONS ISOLATED FROM BONE BIOPSIES AS WELL AS TISSUE-LEVEL BONE FORMATION RATES ON QUADRUPLE-LABELLED BONE BIOPSIES (AIM 3). THE PROPOSED STUDIES WILL RIGOROUSLY TEST WHETHER ATENOLOL IS EFFICACIOUS AND SAFE FOR THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND ALSO FURTHER DEFINE THE MECHANISMS OF SNS EFFECTS ON BONE IN HUMANS. IF OUR PROPOSED CLINICAL TRIAL DEMONSTRATES PROTECTION FROM BONE LOSS IN POSTMENOPAUSAL WOMEN BY ATENOLOL, THIS WOULD FILL A CRUCIAL CLINICAL NEED, AS THESE WOMEN CURRENTLY HAVE VIRTUALLY NO PHARMACOLOGICAL OPTIONS FOR OSTEOPOROSIS PREVENTION.
    assistance · Last action 2025-11-14
    $12,029,156
  • Department of Defense
    OMNI PHYSIOLOGICAL MONITORING WEARABLES
    contract · Last action 2025-09-30
    $11,864,741
  • Department of Defense
    RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
    contract · Last action 2026-01-15
    $11,691,438
  • Department of Health and Human Services
    THE ROLE OF HYPOXIA IN VENOUS NEOINTIMAL HYPERPLASIA IN HEMODIALYSIS GRAFTS
    assistance · Last action 2026-05-20
    $10,363,556
  • Department of Health and Human Services
    THE MACRO- AND MICRO- ANATOMY AND PATHOLOGY OF THE AGING KIDNEY
    assistance · Last action 2026-01-12
    $9,904,839
  • Department of Health and Human Services
    REGIONAL FATTY ACID METABOLISM IN HUMANS
    assistance · Last action 2026-04-03
    $9,595,727
  • Department of Health and Human Services
    ADPKD: DISEASE SPECTRUM & GENOTYPE-PHENOTYPE CORRELATIONS
    assistance · Last action 2026-06-01
    $9,110,694
  • Department of Health and Human Services
    MAYO CLINIC PHYSICAL ACTIVITY RESEARCH CENTER: METABOLOMICS AND PROTEOMICS ANALYSIS SITE
    assistance · Last action 2026-02-11
    $8,876,405
  • Department of Defense
    EFFECTS OF HYPOXIA ON COGNITIVE PERFORMANCE
    contract · Last action 2023-04-26
    $8,856,717
  • Department of Health and Human Services
    POPULATION GENETICS ANALYSIS PROGRAM
    contract · Last action 2015-09-02
    $8,455,976
  • Department of Health and Human Services
    THE EFFECT OF TCF7L2 ON GLUCOSE METABOLISM
    assistance · Last action 2026-06-03
    $8,393,404
  • Department of Health and Human Services
    MAYO CLINIC PROSPECTIVE RESOURCE FOR BIOMARKER VALIDATION AND EARLY DETECTION OF PANCREATIC CANCER
    assistance · Last action 2025-07-29
    $8,248,315
  • Department of Health and Human Services
    NCI, NATIONAL CLINICAL TRIALS NETWORK LEAD ACADEMIC PARTICIPATING SITE (LAPS) UG1
    assistance · Last action 2026-04-01
    $7,885,880
  • Department of Health and Human Services
    DISSECTING THE PATHOGENESIS AND OUTCOMES OF PSC USING MULTI-OMICS BY STUDYING THE EXPOSOME AND GENOME
    assistance · Last action 2026-06-16
    $7,763,082
  • Department of Health and Human Services
    CHARACTERIZING THE FUNTION OF FIBBROCYSTIN AND FIBBROCYSTIN-L
    assistance · Last action 2026-02-12
    $7,670,777
  • Department of Health and Human Services
    CENTER OF INNOVATION FOR BRAIN TUMOR THERAPEUTICS - PROJECT DESCRIPTION/ABSTRACT – OVERALL THE DEVELOPMENT OF EFFECTIVE THERAPIES FOR GLIOBLASTOMA (GBM) HAS BEEN INCREDIBLY VEXING WITH NO NEW DRUG APPROVALS IN OVER A DECADE. THERAPEUTIC RESISTANCE IN ANY ONE PATIENT WITH GBM CAN BE RELATED TO MULTIPLE FACTORS INCLUDING EXTENSIVE TUMOR CELL INFILTRATION INTO ADJACENT BRAIN, MOLECULAR HETEROGENEITY OF TUMOR CELL POPULATIONS, AND HETEROGENEITY OF DRUG DISTRIBUTION. IN ORDER TO UNDERSTAND AND OVERCOME THESE CHALLENGES, WE HAVE BUILT A HIGHLY PRODUCTIVE, MULTI-DISCIPLINARY SCIENTIFIC TEAM OVER THE PAST DECADE WITH EXPERTISE SPANNING SYSTEMS BIOLOGY, PHARMACOLOGY, TUMOR BIOLOGY, AND ANIMAL MODELS OF GBM. IN THE PROPOSED U19 CENTER APPLICATION, WE WILL INTEGRATE THIS ESTABLISHED CROSS-DISCIPLINARY TRANSLATIONAL SCIENCE TEAM WITH PHYSICIAN SCIENTISTS IN RADIATION AND MEDICAL ONCOLOGY, NEUROSURGERY AND NEURORADIOLOGY WITH A COLLECTIVE FOCUS OF TRANSLATING NOVEL THERAPEUTIC STRATEGIES INTO HIGHLY EFFECTIVE THERAPIES FOR PATIENTS WITH GBM. IMPAIRED DDR ENABLES THE GENOMIC INSTABILITY REQUIRED FOR TUMORIGENESIS, AND DIFFERENCES IN DDR FUNCTIONALITY BETWEEN TUMOR AND NORMAL TISSUE PROVIDES THE FUNDAMENTAL RATIONALE FOR USING RADIATION THERAPY OR GENOTOXIC DRUGS AS ANTI-CANCER THERAPIES. ADDITIONAL TARGETED PHARMACOLOGIC DISRUPTION OF DDR IN TUMORS CAN MARKEDLY ENHANCE THE EFFICACY OF THESE CYTOTOXIC THERAPIES AND WIDEN THE THERAPEUTIC WINDOW. IN THIS CONTEXT, WE HAVE COLLABORATED EXTENSIVELY WITH MULTIPLE PHARMACEUTICAL COMPANIES TO EVALUATE VARIOUS SMALL MOLECULE DDR INHIBITORS AND HAVE DEVELOPED SIGNIFICANT PRELIMINARY DATA DEMONSTRATING PROFOUND COMBINATORIAL EFFICACY FOR THESE DRUGS WHEN COMBINED WITH RADIATION OR ALKYLATING CHEMOTHERAPY ROUTINELY USED FOR GBM. THUS, THE INITIAL FOCUS FOR OUR CENTER IS TO OPTIMIZE THE CLINICAL DEPLOYMENT OF DDR INHIBITORS IN COMBINATION WITH CYTOTOXIC THERAPIES FOR GBM. A PHARMACOLOGY CORE WILL SUPPORT BOTH PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) EVALUATIONS IN ANIMAL MODELS AND HUMAN SAMPLES, AND OUR THERAPY EVALUATION CORE WILL SUPPORT BOTH PRE-CLINICAL AND CLINICAL TESTING OF NOVEL THERAPEUTIC STRATEGIES. THE PROJECT AND CORE TEAMS WILL WORK IN CLOSE COLLABORATION TO ACCOMPLISH THE GOALS OF THE CENTER, AND THIS COLLABORATIVE EFFORT WITHIN THE CENTER AND ACROSS THE BROADER GLIOMA THERAPEUTICS NETWORK (GTN) WILL BE COORDINATED BY THE ADMINISTRATIVE CORE.
    assistance · Last action 2026-05-06
    $7,557,918
  • Department of Health and Human Services
    COMPUTATIONAL AND BIOLOGICAL APPROACH TO FLOW DIVERSION
    assistance · Last action 2026-03-25
    $7,406,513
  • Department of Health and Human Services
    PNEUMOCYSTIS CARINII: MACROPHAGE AND EPITHELIAL ACTIVATION
    assistance · Last action 2026-03-20
    $7,047,257
  • Department of Health and Human Services
    EXCEPTIONAL AGING: IDENTIFYING MODIFIERS OF ALZHEIMER'S DISEASE TRAJECTORIES
    assistance · Last action 2026-03-20
    $7,037,574
  • Department of Health and Human Services
    MUSCULOSKELETAL RESEARCH TRAINING PROGRAM
    assistance · Last action 2026-06-11
    $7,007,265
  • Department of Health and Human Services
    MITOCHONDRIAL COMPLEX I AS A TARGET FOR NEUROPROTECTION IN AD
    assistance · Last action 2026-01-20
    $6,988,033
  • Department of Health and Human Services
    TRADE-OFFS IN HUMAN OBSERVER PERFORMANCE, IMAGE QUALITY METRICS, AND PATIENT DOSE
    assistance · Last action 2026-06-01
    $6,952,195
  • Department of Health and Human Services
    PRIME SHOCK AND KILL FOR HIV ERRADICATION
    assistance · Last action 2025-05-13
    $6,945,215
  • Department of Health and Human Services
    STRUCTURE AND FUNCTION OF ACETYLCHOLINE RECEPTORS
    assistance · Last action 2025-04-30
    $6,935,536
  • Department of Health and Human Services
    RESPIRATORY CONTROL IN OLD AGE
    assistance · Last action 2025-07-31
    $6,923,456
  • Department of Health and Human Services
    DISEASE PATHWAYS IN THE POPULATION DETERMINED BY AMYLOID, TAU, AND NEURODEGENERATION IMAGING BIOMARKERS
    assistance · Last action 2026-05-07
    $6,851,916
  • Department of Health and Human Services
    GENETIC STUDIES OF SARCOMERE-BASED CARDIAC DISEASES
    assistance · Last action 2026-06-16
    $6,756,450
  • Department of Health and Human Services
    MAYO CLINIC INTERDISCIPLINARY WOMEN'S HEALTH RESEARCH PROGRAM
    assistance · Last action 2023-07-13
    $6,738,720
  • Department of Health and Human Services
    FFA METABOLISM IN DIFFERENT TYPES OF HUMAN OBESITY
    assistance · Last action 2025-07-31
    $6,716,553
  • Department of Health and Human Services
    MULTIDISCIPLINARY TRAINING IN DIGESTIVE DISEASES
    assistance · Last action 2026-04-09
    $6,610,141

Federal contract dollars to this establishment. Primary NAICS: 622110 - GENERAL MEDICAL AND SURGICAL HOSPITALS. Last action: 2026-06-26. Source: USAspending.gov, net obligations. Recipient address is the SAM registration / HQ address, not necessarily the worksite.

Inspection history

DateTriggerViolationsSeriousPenalty
2013-12-05Planned11$630
1991-10-16Follow-up0—$0
1991-06-03Complaint343$900
1990-08-07Complaint0—$0

Source: OSHA IMIS. Citation amounts reflect initially assessed penalties; final amounts after appeal may differ.

In the news

Part of a larger organization

MAYO CLINIC is one of 32 establishments rolled up under the parent organization Mayo Clinic.

Federal enforcement records on this page represent activity at this specific establishment only. The full enforcement footprint of Mayo Clinic across all 32 of its tracked locations is viewable on the parent profile.

Other employers in this industry and state

Other employers in offices of physicians (except mental health specialists) within MN, ordered by federal enforcement volume:

Other locations under this parent

Other establishments operated by Mayo Clinic, ordered by federal enforcement volume:

Related searches

About this data

This profile aggregates federal enforcement records on MAYO CLINIC from every major federal compliance and enforcement source plus the UVA Corporate Prosecution Registry. OSHA workplace safety inspections, WHD wage cases, MSHA mine safety, EPA environmental enforcement, NLRB labor relations, OFLC visa/labor certification, FMCSA motor carrier registration, SAM.gov debarments, CMS nursing-home records, BLS industry safety benchmarks, OSHA ITA self-reported injury rates, SEC enforcement and financial disclosures, CPSC and NHTSA recalls.

Establishments are matched across agencies using normalized employer name, state, and ZIP code. This establishment resolves to the parent rollup Mayo Clinic, which operates 32 establishments in our dataset.

OSHA citations typically appear 3–8 months after the inspection, so very recent enforcement actions may not yet be reflected. Profiles may be incomplete if the establishment operates under multiple legal names or files under variations our entity-matching rules don’t yet cover. To report a missing record or correction, email corrections@fastdol.com.

Need API access, bulk download, or licensed redistribution? The website is free. Programmatic and licensed access is handled separately.

Contact sales →

Frequently asked

What is MAYO CLINIC's OSHA violation history?
MAYO CLINIC has 4 OSHA inspections on record with 35 violations and $1,530 in total penalties.
How does MAYO CLINIC's safety record compare to its industry?
MAYO CLINIC operates in the offices of physicians (except mental health specialists) industry. The industry average Total Recordable Incident Rate (TRIR) is 1.8. MAYO CLINIC's self-reported DART rate is 0 compared to an industry average of 0.4.